THE FILE ON A WEIGHT-LOSS DRUG THAT MARKETED ITSELF FASTER THAN THE FDA COULD REGULATE IT.
In 2017, the FDA approved semaglutide as a diabetes medication.
THE FILE ON A WEIGHT-LOSS DRUG THAT MARKETED ITSELF FASTER THAN THE FDA COULD REGULATE IT.
In 2017, the FDA approved semaglutide as a diabetes medication. Within four years, it was the most-prescribed weight-loss drug in modern history. Tens of billions of dollars. Off-label scripts. Compounded supply chains. Pediatric approval. The cultural conversation never paused for the regulatory one. This book is the regulatory one.
THE SKINNY SHOT pulls the documentary record on the GLP-1 class. Six years of FDA briefing documents, advisory committee transcripts, trial protocols, post-marketing safety reports, sponsor disclosures, and the price math behind a medication that costs roughly $60 to manufacture and sells for $1,349 a month at the pharmacy counter. Fifteen chapters. 99,000 words.
THE SKINNY SHOT IS INVESTIGATION, NOT ADVICE. It does not recommend treatments. It is the file. Read it, and bring the questions to the physician treating you.
Skriuwer .com
Skriuwer.com is a global community of writers and language enthusiasts dedicated to creating books that inspire, educate, and connect people across cultures. Our name means "writer" in Frisian, reflecting our core mission: we collaborate to produce multilingual content, with a special focus on preserving the Frisian language. It's one of Europe's oldest, related to English and Dutch, and spoken by around 500,000 people in the Netherlands. As a project of the nonprofit De Fryske Wrâld, we direct all profits from book sales into education, outreach, and resources to promote Frisian. This helps combat the challenges of globalization to this vulnerable yet vital language. When you choose our books, you're not just reading; you're supporting a worldwide effort to keep cultural traditions alive.
semaglutide tirzepatide investigation weight loss drug history pharmaceutical FDA advisory committee transcripts post-marketing surveillance adverse events citizen investigation medical journalism GLP-1 investigation FDA weight loss drug history